Highly Specific and Effective Targeting of EGFRvIII-Positive Tumors with TandAb Antibodies

Highly Specific and Effective Targeting of EGFRvIII-Positive Tumors with TandAb Antibodies

To harness the cytotoxic capacity of immune cells for the treatment of solid tumors, we developed tetravalent, bispecific tandem diabody (TandAb) antibodies that recognize EGFRvIII, the deletion variant III of the epidermal growth factor receptor (EGFR), and CD3 on T-cells, thereby directing immune...

Full description

Bibliographic Details
Main Authors: Kristina Ellwanger, Uwe Reusch, Ivica Fucek, Stefan Knackmuss, Michael Weichel, Thorsten Gantke, Vera Molkenthin, Eugene A. Zhukovsky, Michael Tesar, Martin Treder
Format: Article
Language:English
Published: Frontiers Media S.A. 2017-05-01
Series:Frontiers in Oncology
Subjects:
CD3
T cells
bispecific antibodies
tandem diabody
EGFRvIII
glioblastoma multiforme
Online Access:http://journal.frontiersin.org/article/10.3389/fonc.2017.00100/full

Internet

http://journal.frontiersin.org/article/10.3389/fonc.2017.00100/full

Similar Items